Search

Displaying results 3101 - 3110 of 4539 in total
  1. Drug

    AAV-dXIAP

    go.drugbank.com/drugs/DB17880
    Experimental

    AAV-dXIAP is a recombinant adeno-associated virus-encoded gene for X-linked mammalian inhibitor of apoptosis protein (XIAP) developed by Neurologix.

  2. Drug

    Alintegimod

    go.drugbank.com/drugs/DB18879
    Investigational

    Alintegimod is under investigation in clinical trial NCT06362369 (A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy).

  3. Drug

    Adenosine 5'-[gamma-thio]triphosphate

    go.drugbank.com/drugs/DB02930
    Experimental

    A nucleoside triphosphate analogue that is ATP in which one of the oxygens attached to 3-phosphate group is replaced by sulfur.

  4. Drug

    Gliclazide

    go.drugbank.com/drugs/DB01120
    ApprovedInvestigational

    Gliclazide is extensively metabolized by the liver; its metabolites are excreted in both urine (60-70%) and feces (10-20%). … [T238, T360] Gliclazide belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin.

  5. Drug

    Diflorasone

    go.drugbank.com/drugs/DB00223
    Approved

    Diflorasone is a topical corticosteroid used to treat itching and inflammation of the skin.

  6. Drug

    Noscapine

    go.drugbank.com/drugs/DB06174
    Approved

  7. Drug

    XEN-2174

    go.drugbank.com/drugs/DB05012
    Experimental

    In episodes of pain, inhibition of NET by XEN-2174 elevates the levels of NE leading to the activation of inhibitory pathways preventing pain signals from reaching the brain.

  8. Drug

    Nigericin

    go.drugbank.com/drugs/DB14056
    Experimental

    It is produced by Streptomyces hygroscopicus. (From Merck Index, 11th ed)

  9. Drug

    REC-994

    go.drugbank.com/drugs/DB15616
    Investigational

    REC-994 was cleared by the FDA in July, 2018 for a phase I trial for the treatment of cerebral cavernous malformation (CCM).

  10. Drug

    Autologous Hematopoietic Peripheral Blood Stem Cells

    go.drugbank.com/drugs/DB17067
    Investigational

    Autologous hematopoietic peripheral blood stem cells were tested in a clinical trial (NCT00424489) by Northwestern University for the treatment of refractory myasthenia gravis.